Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.
Ham JC, Driessen CM, Hendriks MP, Fiets E, Kreike B, Hoeben A, Slingerland M, van Opstal CC, Kullberg BJ, Jonker MA, Adang EM, Kaanders JH, van der Graaf WT, van Herpen CM. Ham JC, et al. Among authors: driessen cm. Eur J Cancer. 2019 May;113:32-40. doi: 10.1016/j.ejca.2019.02.013. Epub 2019 Apr 6. Eur J Cancer. 2019. PMID: 30965213 Clinical Trial.
Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE Study).
Driessen CM, Ham JC, Te Loo M, van Meerten E, van Lamoen M, Hakobjan MH, Takes RP, van der Graaf WT, Kaanders JH, Coenen MJH, van Herpen CM. Driessen CM, et al. Cancers (Basel). 2019 Apr 17;11(4):551. doi: 10.3390/cancers11040551. Cancers (Basel). 2019. PMID: 30999660 Free PMC article.
Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury.
Klumpers MJ, Witte W, Gattuso G, Schiavello E, Terenziani M, Massimino M, Gidding CEM, Vermeulen SH, Driessen CM, Van Herpen CM, Van Meerten E, Guchelaar HJ, Coenen MJH, Te Loo DMWM. Klumpers MJ, et al. J Pers Med. 2022 May 28;12(6):892. doi: 10.3390/jpm12060892. J Pers Med. 2022. PMID: 35743677 Free PMC article.
Establishing reference curves for vital tissue perfusion using quantitative near-infrared fluorescence imaging with indocyanine green.
Tange FP, Peul RC, van den Hoven P, Koning S, Kruiswijk MW, Faber RA, Verduijn PS, van Rijswijk CSP, Galema HA, Hilling DE, van Dijk SPJ, van Ginhoven TM, Keereweer S, Mureau MAM, Feitsma EA, Noltes ME, Kruijff S, Driessen C, Achiam MP, Schepers A, van Schaik J, Mieog JSD, Vahrmeijer AL, Hamming JF, van der Vorst JR. Tange FP, et al. Among authors: driessen c. Langenbecks Arch Surg. 2025 Jan 8;410(1):28. doi: 10.1007/s00423-024-03589-1. Langenbecks Arch Surg. 2025. PMID: 39777554 Free PMC article.
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.
Weijers JAM, Verhaegh GW, Lassche G, van Engen-van Grunsven ACH, Driessen CML, van Erp NP, Jonker MA, Schalken JA, van Herpen CML. Weijers JAM, et al. Among authors: driessen cml. BMC Cancer. 2024 Sep 20;24(1):1174. doi: 10.1186/s12885-024-12889-0. BMC Cancer. 2024. PMID: 39304797 Free PMC article.
Long-term results and patient-reported outcomes after vascularized fibular graft use in the treatment of post-traumatic bone defects of femur shaft and tibia: A retrospective cohort and cross-sectional survey study.
Noorlander-Borgdorff MP, Alkemade E, van der Sluis WB, de Jong T, Driessen C, Giannakópoulos GF, Smit JM, van Embden D, Winters H, Botman M. Noorlander-Borgdorff MP, et al. Among authors: driessen c. J Plast Reconstr Aesthet Surg. 2024 Nov;98:144-157. doi: 10.1016/j.bjps.2024.08.056. Epub 2024 Sep 7. J Plast Reconstr Aesthet Surg. 2024. PMID: 39255522 Free article.
The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
Janssen JBE, Brahm CG, Driessen CML, Nuver J, Labots M, Kouwenhoven MCM, Sanchez Aliaga E, Enting RH, de Groot JC, Walenkamp AME, van Linde ME, Verheul HMW. Janssen JBE, et al. Among authors: driessen cml. Brain Commun. 2024 Jul 30;6(4):fcae241. doi: 10.1093/braincomms/fcae241. eCollection 2024. Brain Commun. 2024. PMID: 39114330 Free PMC article. Clinical Trial.
265 results